An FDA advisory panel deemed the Neovasc Reducer instrument protected for treating refractory angina but almost unanimously voted against its efficacy, the corporate launched. (BioSpace)…
An FDA advisory panel deemed the Neovasc Reducer instrument protected for treating refractory angina but almost unanimously voted against its efficacy, the corporate launched. (BioSpace)…